Scripps research scientists develop innovative dual action anthrax vaccine-antitoxin combinationOctober 05, 2007New compound could provide rapid treatment and long-term protection in a single injection The immune response generated in rats by the new agent protects against lethal toxin exposure after only one injection, and is faster and stronger than any currently available vaccine. The new study, led by Scripps Research scientists Anette Schneemann and Marianne Manchester, and Salk Institute Professor John A.T. Young, was published in the October 5 issue of the journal PLoS Pathogens (Volume 3, Issue 10).
"The new anti-anthrax agent that we developed is an important and potentially critical development for anyone who works with the bacterium or those who might be exposed to it in a bioterrorism attack," Schneemann said. "While other strategies are being pursued to develop improved anthrax vaccines, none of these offer the distinct advantage of combining the function of a vaccine with a potent antitoxin." Concerns about anthrax-a potentially fatal disease caused by the spore-forming, gram-positive bacterium Bacillus anthracis-as a weapon of bioterrorism has prompted increased efforts to develop better antitoxins and vaccines. The current vaccine, which was developed in the 1950s, is safe and effective, but requires multiple injections followed by annual boosters. Current anthrax treatment involves antibiotics such as ciprofloxacin and doxycycline that attack the bacteria but provide no protection against the dangerous toxins secreted by the bacteria. The new study introduces a highly effective dual-action compound that leapfrogs current efforts to develop a second-generation anthrax vaccine. In the research, the scientists created a "multivalent display," with several sites of attachment for recombinant protective antigen protein (PA), the primary component of the current anthrax vaccine, rather than only one. Virus-like particles coated with PA were found to produce a potent toxin-neutralizing antibody response that protected rats from the lethal anthrax toxin after only a single immunization. The antitoxin strategy arose from the discovery of the anthrax toxin receptor, ANTXR2, in the Young lab. "The new anti-anthrax agent is based on a multivalent display of ANTXR2 on the surface of an insect virus," explains Schneemann. "Our approach was based on the assumption that a multivalent display of recombinant protective antigen protein would induce a far more potent immune response. That turned out to be correct." Specifically, the new vaccine-antitoxin combination is based on the multivalent display (180 copies) of the PA-binding von Willebrand A (VWA) domain of the ANTXR2 cellular receptor on the Flock House virus. The chimeric virus-like particle platform, which produces protective immunity and has been shown to be safe, inhibited lethal toxin action in in vitro and in vivo models of anthrax infection. In fact, rats survived exposure to the toxin four weeks after a single injection of the new double-acting agent. This result suggests an extremely rapid production of neutralizing antibodies without the use of an adjuvant, a secondary agent that helps stimulate the immune system and is often used to increase the vaccine response-key goals for the development of third-generation anthrax vaccines. In addition to its use against anthrax, Schneemann notes that creating a multivalent platform may also have the potential to work against other infectious agents. "One important reason for the success of this project is that it arose from the multidisciplinary and highly collaborative efforts of our team of microbiologists, structural biologists, and immunologists," said Manchester, who headed a National Institutes of Health (NIH)-funded program project grant that supported the work. Scripps Research Institute | |||||||||||||||||||||
|
Related Anthrax Current Events and Anthrax News Articles Nature study demonstrates that bacterial clotting depends on clustering Bacteria can directly cause human blood and plasma to clot-a process that was previously thought to have been lost during the course of vertebrate evolution, according to new research at the University of Chicago, National Institute of Allergy and Infectious Diseases, and Institut Pasteur in Paris. Their findings will be published online Nov. 2 in Nature Chemical Biology. UCLA develops safer, more effective TB vaccine for HIV-positive people UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials. Green catalysts provide promise for cleaning toxins and pollutants Tetra-Amido Macrocyclic Ligands (TAMLs) are environmentally friendly catalysts with a host of applications for reducing and cleaning up pollutants, and a prime example of "green chemistry." Carnegie Mellon University's Terry Collins, the catalyst's inventor, believes that the small-molecule catalysts have the potential to be even more effective than previously proven. Nano vaccine for hepatitis B shows promise for third world Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. Francisella tularensis: Stopping a biological weapon Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Until recently we knew very little about this bacterium. Effective health messages may yield vaccine compliance among ER workers Emergency room workers will be the first line of defense in the event of a disease pandemic and will be forced to deal with the chaos that inevitably comes with treating thousands of sick and dying. In order to protect themselves and allow them to care for the public, these first responders need to be fully prepared by getting available vaccines now. Tests show LLNL detection instrument can monitor the air for all major terrorist threat substances Security and law enforcement officials may some day have a new ally - a universal detection system that can monitor the air for virtually all of the major threat agents that could be used by terrorists. New strategies against bird flu The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS). NIST, Army researchers pave the way for anthrax spore standards Researchers from the National Institute of Standards and Technology (NIST) and the U.S. Army Dugway (Utah) Proving Ground have developed reliable methods based on DNA analysis to assess the concentration and viability of anthrax spores after prolonged storage. Protein data bank archives 50,000th molecule structure The Protein Data Bank (PDB) based at Rutgers, The State University of New Jersey, and the University of California-San Diego (UCSD) this month reached a significant milestone in its 37-year history. The 50,000th molecule structure was released into its archive, joining other structures vital to pharmacology, bioinformatics and education. More Anthrax Current Events and Anthrax News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||